CompletedNot Applicable

Alfuzosin and Mirabegron for Double-J Stent Symptoms

Turkey (Türkiye)100 participantsStarted 2024-06-01

Plain-language summary

This prospective randomized controlled trial investigates the effects of alfuzosin, mirabegron, and their combination on stent-related symptoms and outcomes in patients undergoing DJ stent placement after retrograde intrarenal surgery (RIRS) for renal stones. The primary outcomes include stone-free rate and residual fragment status, while secondary outcomes focus on stent-related pain and lower urinary tract symptoms (LUTS). Patients will be randomly assigned to one of four groups: alfuzosin only, mirabegron only, combination therapy, or control. Pain and LUTS will be assessed using validated questionnaires such as the Ureteral Stent Symptom Questionnaire (USSQ) and IPSS.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Undergoing RIRS and DJ stenting Ability to provide informed consent Exclusion Criteria: * Neurogenic bladder Prostate volume \>40 mL or significant LUTS at baseline Contraindications to alpha-blockers or mirabegron Hepatic or severe renal impairment

What they're measuring

Stent-Related Pain Score

Timeframe: Day 7 postoperatively and Day 14 postoperatively.

Lower Urinary Tract Symptom (LUTS) Score

Timeframe: Day 7 postoperatively and Day 14 postoperatively

Trial details

NCT IDNCT07018934

SponsorUniversity of Gaziantep

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-04-01

View on ClinicalTrials.gov More Ureteral Stent-Related Symptoms trials